BiotechComparator (@BioComparator) header
BiotechComparator (@BioComparator) profile picture

BiotechComparator

@BioComparator

Biotech catalysts, evidence placement. https://xitter.cf/t.co/xUhitOhmEz

Joined July 2014
  • Tweets94
  • Following93
  • Followers66
84Media
Photo by BiotechComparator (@BioComparator)Photo by BiotechComparator (@BioComparator)Photo by BiotechComparator (@BioComparator)Photo by BiotechComparator (@BioComparator)Photo by BiotechComparator (@BioComparator)Photo by BiotechComparator (@BioComparator)Photo by BiotechComparator (@BioComparator)Photo by BiotechComparator (@BioComparator)Photo by BiotechComparator (@BioComparator)Photo by BiotechComparator (@BioComparator)
BiotechComparator retweeted
NEJM (@NEJM) profile picture
NEJM
@NEJMSep 29
In the phase 3 TRIUMPH-1 trial involving patients with obesity, retatrutide, a triple hormone receptor agonist, resulted in substantial weight reduction and a decrease in knee osteoarthritis pain and obstructive sleep apnea events. Full trial results: nej.md/4ycgSHz
A graph from an Original Article published in the New England Journal of Medicine article titled "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity." The graph shows effect of retatrutide on body weight. The trial name, TRIUMPH-1, is in parentheses after the title. The NEJM identity sits at the bottom.

ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity." The graph shows effect of retatrutide on body weight. The trial name, TRIUMPH-1, is in parentheses after the title. The NEJM identity sits at the bottom.

26
262
112
1,089
416,142
Load more